No need to panic about Caleb Williams; the Chicago Bears have the blueprint to propel him into a star quarterback in Year 2.

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 billion. Blueprint specializes in systemic mastocytosis and other ...

Sanofi SA will buy Blueprint Medicines Corp. for $9.1 billion equity value, in a deal that sees the European pharmaceutical firm expand its rare immunological disease portfolio.

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European ...

After signaling its intent to make "bolt-on acquisitions," Sanofi has taken a major plunge, buying out Blueprint Medicines for $9.5 billion.

Cambridge-based Blueprint Medicines brings a pipeline of experimental immunology treatments and one medicine already on sale for a rare condition known as systemic mastocytosis.

During this year’s legislative session in Annapolis, changes were made to the Blueprint for Maryland’s Future to ease financial pressure on districts. But one state senator says the law is ...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

Sanofi will pay $129.0 in cash for each share in Blueprint, representing an equity value of $9.1 billion. The figure is also a 27.3% premium to Blueprint’s Friday close.

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

Sanofi plans to buy Blueprint Medicines in a deal worth more than $9 billion, expanding its immunology pipeline ...